{"analyses":[{"ciLowerLimit":"0.394","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.550","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.466","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Here 'NA' represents that upper limit of 95% CI was not estimable due to lesser number of events.","groupId":"OG000","lowerLimit":"29.57","upperLimit":"NA","value":"33.02"},{"groupId":"OG001","lowerLimit":"14.69","upperLimit":"18.27","value":"14.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 \\[PCWG2\\] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors \\[RECIST\\] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.","id":"OG000","title":"Abiraterone Acetate+Prednisone+ADT"},{"description":"Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.","id":"OG001","title":"Placebo + ADT"}],"paramType":"MEDIAN","populationDescription":"Intention to treat (ITT) analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 44 months","title":"Radiographic Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}